Turn Therapeutics (TTRX) Debt to Equity (2025 - 2026)
Turn Therapeutics (TTRX) recorded quarterly Debt to Equity of $1.42 in Q1 2026, up 120.19% quarter-over-quarter from $0.65 in Q4 2025.
Turn Therapeutics (TTRX) Debt to Equity (2025 - 2026) Analysis & Trends
Turn Therapeutics' Debt to Equity history runs 2 years deep, the most recent figure standing at $1.42 for Q1 2026.
- In Q1 2026, Debt to Equity changed N/A year-over-year to $1.42; the TTM figure through Mar 2026 stood at $1.42 (changed N/A YoY), while the FY2025 annual figure was $0.65, changed N/A from the prior year.
- Debt to Equity was $1.42 for Q1 2026 at Turn Therapeutics, up from $0.65 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.42 in Q1 2026 to a low of $0.65 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Turn Therapeutics | 175.38 Mn | 175.38 Mn | - | 1.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.42 |
| Dec 31, 2025 | 0.65 |